SIGN UP FOR UPDATES!
Sign up for Englemed updates from TwitterSign up for Englemed updates from Facebook
ENGLEMED
Contact Englemed
Our contact email address.
We can provide a specialist, tailored health and medical news service for your site.
Click here for more information
RSS graphic XML Graphic Add to Google
About Englemed news services - services and policies.
Englemed News Blog - Ten years and counting.
Diary of a reluctant allergy sufferer - How the British National Health Service deals with allergy.
BOOKS AND GIFTS THIS WAY!
BookshopFor books on women's health, healthy eating ideas, mental health issues, diabetes, etc click here
SEARCH THIS SITE
Google

WWW Englemed
Copyright Notice. All reports, text and layout copyright Englemed Ltd, 52 Perry Avenue, Birmingham UK B42 2NE. Co Registered in England No 7053778 Some photos copyright Englemed Ltd, others may be used with permission of copyright owners.
Disclaimer: Englemed is a news service and does not provide health advice. Advice should be taken from a medical professional or appropriate health professional about any course of treatment or therapy.
FreeDigitalPhotos
www.freedigitalphotos.net
FreeWebPhotos
www.freewebphoto.com
FROM OUR NEWS FEEDS
Caution urged in Europe over summer easing
Fri June 11th - The World Health Organisation has urged caution as European countries seek to ease pandemic restrictions over the summer. More
RECENT COMMENTS
On 09/10/2020 William Haworth wrote:
How long is recovery time after proceedure... on Ablation cuts atrial fibrillat...
On 08/02/2018 David Kelly wrote:
Would you like to write a piece about this to be i... on Researchers unveil new pain re...
On 23/10/2017 Cristina Pereira wrote:
https://epidemicj17.imascientist.org.uk/2017/06/21... on HIV breakthrough - MRC...
On 12/09/2017 Aparna srikantam wrote:
Brilliant finding! indeed a break through in under... on Leprosy research breakthrough...
On 01/07/2017 Annetta wrote:
I have been diagnosed with COPD for over 12 years.... on Seaweed plan for antimicrobial...
OUR CLIENTS
THIS WEEK'S STORIES
ENGLEMED HEALTH NEWS

Blood enzyme may explain male virus susceptibility

Monday May 11th, 2020

The ACE2 enzyme may help explain why men are more vulnerable to the Covid-19 virus than women, Dutch researchers report today.

The study also found that patients taking ace-inhibitors and other related drugs did not suffer this vulnerability, according to a report in the European Heart Journal.

The study is the latest to examine the links between viral infection and various cardiovascular disease factors.

Researchers at the University Medical Centre, Groningen, studied in total more than 3,700 heart failure patients in 11 European countries.

They sought to analyse factors linked to increased rates of ACE2 - angiotensin converting enzyme 2 - and found that male gender was the strongest predictive factor.

The researchers say ACE2 is important because it helps Covid-19 to infect healthy cells.

According to the analysis, not just ACE inhibitors but angiotensin receptor blockers and renin-angiotensin-aldosterone system drugs were associated with normal blood levels of ACE2.

Researcher Professor Adrian Voors said: “Our findings do not support the discontinuation of these drugs in COVID-19 patients as has been suggested by earlier reports.

“ACE2 is a receptor on the surface of cells. It binds to the coronavirus and allows it to enter and infect healthy cells after it has been modified by another protein on the surface of the cell, called TMPRSS2. High levels of ACE2 are present in the lungs and, therefore, it is thought to play a crucial role in the progression of lung disorders related to COVID-19.”

Writing in the journal, Professor Marc Pfeffer, from Brigham and Women’s Hospital, Harvard Medical School, USA, and Professor Gavin Oudit, from the University of Alberta, Canada, write: "This field is moving so rapidly that we now have two observational studies of ARB/ACE inhibitor use in hospitalised Covid-19 patients showing no augmented risk to Covid-19 patients and even suggesting possible benefit.”

* A triple combination of anti-viral drugs is showing early promise in treating the disease, according to a report in The Lancet.

Doctors in Hong Kong set up a randomised trial involving 127 patients to test interferon beta-1b, lopinavir-ritonavir and ribavirin. They found it shorted the duration of viral shedding from 12 days to seven days in comparison with lopinavir-ritonavir.

Professor Kwok-Yung Yuen, from the University of Hong Kong, said: "Our trial demonstrates that early treatment of mild to moderate COVID-19 with a triple combination of antiviral drugs may rapidly suppress the amount of virus in a patient's body, relieve symptoms, and reduce the risk to health-care workers by reducing the duration and quantity of viral shedding (when the virus is detectable and potentially transmissible). Furthermore, the treatment combination appeared safe and well tolerated by patients."

Circulating plasma concentrations of angiotensin-converting enzyme 2 in men and women with heart failure and effects of renin-angiotensin-aldosterone inhibitors. European Heart Journal 11 May 2020; doi:10.1093/eurheartj/ehaa373

https://academic.oup.com/eurheartj/article-lookup/doi/10.1093/eurheartj/ehaa373

Lancet 8 May 2020

http://www.thelancet.com/journals/lancet/article/PIIS0140-6736(20)31042-4/fulltext

Tags: Asia | Europe | Flu & Viruses | Men's Health

Printer friendly page Printer friendly page

Comment on this article:

Name:
Email:
Comment:
<a>,<b> & <p> tags allowed
Please enter the letters displayed:
(not case sensitive)
CATEGORIES